Literature DB >> 18356264

Predicted biological activity of intravitreal VEGF Trap.

M W Stewart1, P J Rosenfeld.   

Abstract

AIM: To compare the intravitreal binding activity of VEGF Trap with that of ranibizumab against vascular endothelial growth factor (VEGF) using a time-dependent and dose-dependent mathematical model.
METHODS: Intravitreal half-lives and relative equimolar VEGF-binding activities of VEGF Trap and ranibizumab were incorporated into a first-order decay model. Time-dependent VEGF Trap activities (relative to ranibizumab) for different initial doses (0.5, 1.15, 2 and 4 mg) were calculated and plotted.
RESULTS: Seventy-nine days after a single VEGF Trap (1.15 mg) injection, the intravitreal VEGF-binding activity would be comparable to ranibizumab at 30 days. After injection of 0.5, 2 and 4 mg VEGF Trap, the intravitreal VEGF-binding activities (comparable to ranibizumab at 30 days) would occur at 73, 83 and 87 days, respectively
CONCLUSION: On the basis of this mathematical model, VEGF Trap maintains significant intravitreal VEGF-binding activity for 10-12 weeks after a single injection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356264     DOI: 10.1136/bjo.2007.134874

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  109 in total

1.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-13       Impact factor: 3.117

2.  Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.

Authors:  Cheolmin Yun; Jaeryung Oh; Jaemoon Ahn; Soon-Young Hwang; Boram Lee; Seong-Woo Kim; Kuhl Huh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-19       Impact factor: 3.117

Review 3.  Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2014-08-01

4.  Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.

Authors:  Jesse J Jung; Quan V Hoang; Mohammad Z Y Arain; Stanley Chang
Journal:  Acta Ophthalmol       Date:  2015-09-24       Impact factor: 3.761

5.  VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.

Authors:  Cecilia S Lee; Alisa J Kim; Douglas Baughman; Catherine Egan; Clare Bailey; Robert L Johnston; Salim Natha; Rehna Khan; Christopher Brand; Toks Akerele; Martin McKibbin; Louise Downey; Saher Al-Husainy; Aaron Y Lee; Adnan Tufail
Journal:  Retina       Date:  2018-05       Impact factor: 4.256

6.  Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.

Authors:  Florian M Heussen; Qing Shao; Yanling Ouyang; Antonia M Joussen; Bert Müller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-24       Impact factor: 3.117

7.  Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.

Authors:  Shigeyuki Ijiri; Kazuhisa Sugiyama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-13       Impact factor: 3.117

8.  Intravitreal aflibercept for choroidal neovascularisation in angioid streaks.

Authors:  S Vaz-Pereira; L Collaço; G De Salvo; P van Zeller
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775

9.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

10.  Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.

Authors:  Marta S Figueroa; Inés Contreras
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.